CN101563085A - 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物 - Google Patents

作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物 Download PDF

Info

Publication number
CN101563085A
CN101563085A CNA2007800392650A CN200780039265A CN101563085A CN 101563085 A CN101563085 A CN 101563085A CN A2007800392650 A CNA2007800392650 A CN A2007800392650A CN 200780039265 A CN200780039265 A CN 200780039265A CN 101563085 A CN101563085 A CN 101563085A
Authority
CN
China
Prior art keywords
dihydro
alkyl
isoquinolin
phenyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800392650A
Other languages
English (en)
Chinese (zh)
Inventor
J-M·韦尼耶
M·A·德拉罗沙
H·陈
J·Z·吴
G·L·拉森
I·W·切尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch Health Americas Inc
Original Assignee
Valeant Pharmaceuticals International Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Pharmaceuticals International Inc USA filed Critical Valeant Pharmaceuticals International Inc USA
Publication of CN101563085A publication Critical patent/CN101563085A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2007800392650A 2006-08-23 2007-08-22 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物 Pending CN101563085A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83994106P 2006-08-23 2006-08-23
US60/839,941 2006-08-23

Publications (1)

Publication Number Publication Date
CN101563085A true CN101563085A (zh) 2009-10-21

Family

ID=39107384

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800392650A Pending CN101563085A (zh) 2006-08-23 2007-08-22 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物

Country Status (23)

Country Link
US (1) US8293911B2 (enExample)
EP (1) EP2061465B1 (enExample)
JP (1) JP5419691B2 (enExample)
KR (1) KR20090079191A (enExample)
CN (1) CN101563085A (enExample)
AR (1) AR062508A1 (enExample)
AU (1) AU2007288253B2 (enExample)
BR (1) BRPI0716715B1 (enExample)
CA (1) CA2661462C (enExample)
CL (1) CL2007002455A1 (enExample)
DK (1) DK2061465T3 (enExample)
ES (1) ES2420960T3 (enExample)
IL (1) IL197161A (enExample)
MX (1) MX2009002002A (enExample)
NO (1) NO343575B1 (enExample)
NZ (1) NZ575652A (enExample)
PL (1) PL2061465T3 (enExample)
PT (1) PT2061465E (enExample)
RU (1) RU2009110172A (enExample)
SG (1) SG174095A1 (enExample)
TW (1) TW200827339A (enExample)
WO (1) WO2008024398A2 (enExample)
ZA (1) ZA200901977B (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869250A (zh) * 2010-02-01 2013-01-09 威朗国际制药公司 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺衍生物
CN102971307A (zh) * 2010-07-08 2013-03-13 辉瑞大药厂 作为kv7钾通道开放剂的哌啶基嘧啶酰胺
CN103694163A (zh) * 2012-09-27 2014-04-02 上海先声药物研究有限公司 作为钾通道调节剂的化合物
CN108203395A (zh) * 2016-12-20 2018-06-26 国际香料和香精公司 新型感官化合物
CN109641836A (zh) * 2016-06-10 2019-04-16 赛弗卢尔生命科学公司 氟化的2-氨基-4-(取代的氨基)苯基氨基甲酸酯衍生物
CN111954663A (zh) * 2017-12-13 2020-11-17 赛弗卢尔生命科学公司 氟化的4-(取代的氨基)苯基氨基甲酸酯衍生物
CN112384216A (zh) * 2018-05-11 2021-02-19 泽农医药公司 用于增强生物利用度和电压门控钾离子通道开放暴露的方法
CN114667146A (zh) * 2019-11-08 2022-06-24 泽农医药公司 治疗抑郁症的方法
CN114786658A (zh) * 2019-12-06 2022-07-22 泽农医药公司 Kv7钾离子通道开放剂治疗疼痛的用途
WO2022174667A1 (zh) * 2021-10-27 2022-08-25 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用
CN115190874A (zh) * 2019-10-10 2022-10-14 泽农医药公司 一种选择性钾通道调节剂的固态结晶形式
WO2023125935A1 (zh) * 2021-12-31 2023-07-06 上海翰森生物医药科技有限公司 苯并哌啶衍生物调节剂、其制备方法和应用
CN116847843A (zh) * 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂
WO2024067819A1 (zh) * 2022-09-30 2024-04-04 上海翰森生物医药科技有限公司 含哌啶多环类衍生物调节剂、其制备方法和应用
US12319656B2 (en) 2021-10-27 2025-06-03 Shanghai Zhimeng Biopharma, Inc. Compound as potassium channel regulator and preparation and use thereof
WO2025167886A1 (zh) * 2024-02-08 2025-08-14 上海挚盟医药科技有限公司 四氢异喹啉基化合物的晶型及其应用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
AU2007288253B2 (en) 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
WO2008066900A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AU2009271302A1 (en) 2008-06-24 2010-01-21 Valeant Pharmaceuticals International Benzyloxy anilide derivatives useful as potassium channel modulators
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
IN2014CN02806A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
JP6033318B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
PL2766346T3 (pl) 2011-10-14 2017-09-29 Bristol-Myers Squibb Company Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA
CN103073455B (zh) 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
JP2021510699A (ja) 2018-01-10 2021-04-30 アリンキー バイオファーマＡｌｌｉｎｋｙ Ｂｉｏｐｈａｒｍａ テトラヒドロイソキノリン化合物
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
EP3870291A1 (en) 2018-10-22 2021-09-01 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
EP3917907B1 (en) 2019-01-29 2025-05-21 Universitá Degli Studi Di Salerno Modulators of potassium ion channels and uses thereof
CN114057641B (zh) * 2020-08-07 2025-02-18 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用
PE20231856A1 (es) 2021-02-09 2023-11-21 Xenon Pharmaceuticals Inc Terapia conjunta para el tratamiento de trastornos convulsivos
JP7681132B2 (ja) * 2021-08-26 2025-05-21 紐欧申医薬（上海）有限公司 カリウムチャネル調節剤、組成物及び使用
CN116478068A (zh) 2022-01-14 2023-07-25 中国科学院上海药物研究所 一种高选择性kcnq4钾通道激动剂、其制备方法和用途
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用
US20240101531A1 (en) 2022-06-08 2024-03-28 Xenon Pharmaceuticals Inc. Pyridinamine derivatives and their use as potassium channel modulators
CN120435316A (zh) * 2022-08-30 2025-08-05 拜奥海芬治疗学有限公司 包括金属通道激活剂和nmda受体拮抗剂的组合疗法
TW202521516A (zh) 2023-08-17 2025-06-01 加拿大商再諾製藥公司 氮雜環庚烷及吡咯啶化合物及其用途
TW202521541A (zh) 2023-08-17 2025-06-01 加拿大商再諾製藥公司 雜芳基胺化合物及其用途
TW202517257A (zh) * 2023-09-19 2025-05-01 加拿大商再諾製藥公司 氘及芳胺化合物及其用途
WO2025179128A1 (en) 2024-02-22 2025-08-28 Xenon Pharmaceuticals Inc. Azetukalner for use in the treatment of depression, anhedonia or a seizure disorder such as epilepsy in pediatric subjects

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181803A (en) * 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
ATE25078T1 (de) * 1982-10-27 1987-02-15 Degussa 2-amino-3-acylamino-6-benzylamino-pyridinderivate mit anti-epileptischer wirkung.
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
DE3663775D1 (en) * 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
JP2583067B2 (ja) * 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) * 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) * 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (enExample) * 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) * 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) * 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) * 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
USRE38115E1 (en) * 1994-09-22 2003-05-06 Center For Neurologic Study Dextromethorphan and an oxidase inhibitor for treating intractable conditions
US5679706A (en) * 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
ES2377126T3 (es) * 1994-12-12 2012-03-22 Omeros Corporation Solución de irrigación y utilización de la misma para la inhibición perioperatoria del dolor, la inflamación y/o los espasmos en una estructura vascular
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
ES2251095T3 (es) * 1997-08-08 2006-04-16 Chugai Seiyaku Kabushiki Kaisha Agentes terapeuticos para complicaciones diabeticas.
US6593335B1 (en) * 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6265417B1 (en) * 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
JP2000143510A (ja) 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
CN1526448A (zh) * 1998-12-14 2004-09-08 ���ռ�ҩ��ɷ����޹�˾ 用于治疗肛门直肠病的药物和方法
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
US6451857B1 (en) * 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6436923B1 (en) 1999-03-17 2002-08-20 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AT409083B (de) * 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
HRP20020013A2 (en) 1999-07-06 2003-08-31 Lilly Co Eli SELECTIVE iGluR<SUB>5</SUB> RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
DE60037321D1 (de) * 1999-08-04 2008-01-17 Icagen Inc Benzanilide als öffner des kaliumkanals
CA2378243C (en) * 1999-08-04 2012-05-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) * 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
US6831080B2 (en) * 2001-05-31 2004-12-14 Bristol-Myers Squibb Company Cinnamide derivatives as KCNQ potassium channel modulators
GB0121214D0 (en) * 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
AU2003202115A1 (en) 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
AUPS110302A0 (en) * 2002-03-14 2002-04-18 Biomolecular Research Institute Limited Novel chalcone derivatives and uses thereof
EP1506166B1 (en) 2002-05-17 2011-11-16 Janssen Pharmaceutica NV Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2003106454A1 (en) * 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd 1h-isoquinoline-oxazolidinone derivaties and their use as antibacterial agents
AUPS312602A0 (en) * 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
AU2003294441A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
WO2004058704A2 (en) * 2002-12-23 2004-07-15 Icagen, Inc. Quinazolinones as potassium channel modulators
PT1578740E (pt) 2002-12-27 2007-05-31 Lundbeck & Co As H Derivados de 1, 2, 4-triaminobenzeno úteis para tratamento de distúrbios do sistema nervoso central
JP2006520333A (ja) 2003-03-14 2006-09-07 ハー・ルンドベック・アクチエゼルスカベット 置換されたアニリン誘導体
MXPA05010000A (es) 2003-03-21 2005-11-17 Lundbeck & Co As H Derivados de p-diaminobenceno substituidos.
US20060264496A1 (en) 2003-04-25 2006-11-23 H. Lundbeck A/S Substituted indoline and indole derivatives
US20060241134A1 (en) 2003-05-27 2006-10-26 Altana Pharma Ga Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
JP2007505142A (ja) * 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
AU2004289186B2 (en) * 2003-09-23 2010-12-16 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
CA2560346A1 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
US20050277579A1 (en) * 2004-05-03 2005-12-15 Ranga Krishnan Compositions for affecting weight loss
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
WO2006054513A1 (ja) 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. 神経因性疼痛の予防又は治療剤
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US7812020B2 (en) 2005-03-03 2010-10-12 H. Lundbeck A/S Substituted pyridine derivatives
US7683058B2 (en) * 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
AU2007288253B2 (en) 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
WO2008066900A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869250A (zh) * 2010-02-01 2013-01-09 威朗国际制药公司 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺衍生物
CN102971307A (zh) * 2010-07-08 2013-03-13 辉瑞大药厂 作为kv7钾通道开放剂的哌啶基嘧啶酰胺
CN103694163A (zh) * 2012-09-27 2014-04-02 上海先声药物研究有限公司 作为钾通道调节剂的化合物
WO2014048165A1 (zh) * 2012-09-27 2014-04-03 上海先声药物研究有限公司 作为钾通道调节剂的化合物
CN109641836A (zh) * 2016-06-10 2019-04-16 赛弗卢尔生命科学公司 氟化的2-氨基-4-(取代的氨基)苯基氨基甲酸酯衍生物
CN108203395B (zh) * 2016-12-20 2022-09-16 国际香料和香精公司 感官化合物
CN108203395A (zh) * 2016-12-20 2018-06-26 国际香料和香精公司 新型感官化合物
CN111954663A (zh) * 2017-12-13 2020-11-17 赛弗卢尔生命科学公司 氟化的4-(取代的氨基)苯基氨基甲酸酯衍生物
CN112384216A (zh) * 2018-05-11 2021-02-19 泽农医药公司 用于增强生物利用度和电压门控钾离子通道开放暴露的方法
CN120549930A (zh) * 2018-05-11 2025-08-29 泽农医药公司 用于增强生物利用度和电压门控钾离子通道开放暴露的方法
CN115190874A (zh) * 2019-10-10 2022-10-14 泽农医药公司 一种选择性钾通道调节剂的固态结晶形式
CN114667146A (zh) * 2019-11-08 2022-06-24 泽农医药公司 治疗抑郁症的方法
CN114786658A (zh) * 2019-12-06 2022-07-22 泽农医药公司 Kv7钾离子通道开放剂治疗疼痛的用途
CN116847843A (zh) * 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂
WO2022174667A1 (zh) * 2021-10-27 2022-08-25 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用
US12319656B2 (en) 2021-10-27 2025-06-03 Shanghai Zhimeng Biopharma, Inc. Compound as potassium channel regulator and preparation and use thereof
WO2023125935A1 (zh) * 2021-12-31 2023-07-06 上海翰森生物医药科技有限公司 苯并哌啶衍生物调节剂、其制备方法和应用
WO2024067819A1 (zh) * 2022-09-30 2024-04-04 上海翰森生物医药科技有限公司 含哌啶多环类衍生物调节剂、其制备方法和应用
WO2025167886A1 (zh) * 2024-02-08 2025-08-14 上海挚盟医药科技有限公司 四氢异喹啉基化合物的晶型及其应用

Also Published As

Publication number Publication date
AR062508A1 (es) 2008-11-12
RU2009110172A (ru) 2010-09-27
NO343575B1 (no) 2019-04-08
EP2061465A4 (en) 2011-03-16
PT2061465E (pt) 2013-07-15
NO20091183L (no) 2009-05-08
BRPI0716715A2 (pt) 2013-09-03
AU2007288253B2 (en) 2013-05-02
PL2061465T3 (pl) 2014-03-31
JP5419691B2 (ja) 2014-02-19
CA2661462C (en) 2015-09-29
ES2420960T3 (es) 2013-08-28
EP2061465B1 (en) 2013-04-10
EP2061465A2 (en) 2009-05-27
KR20090079191A (ko) 2009-07-21
WO2008024398B1 (en) 2008-08-14
IL197161A0 (en) 2009-12-24
WO2008024398A2 (en) 2008-02-28
AU2007288253A1 (en) 2008-02-28
SG174095A1 (en) 2011-09-29
ZA200901977B (en) 2010-02-24
JP2010501568A (ja) 2010-01-21
CL2007002455A1 (es) 2008-04-18
TW200827339A (en) 2008-07-01
US20080139610A1 (en) 2008-06-12
US8293911B2 (en) 2012-10-23
CA2661462A1 (en) 2008-02-28
NZ575652A (en) 2011-08-26
DK2061465T3 (da) 2013-07-08
IL197161A (en) 2015-07-30
MX2009002002A (es) 2009-07-22
BRPI0716715B1 (pt) 2021-07-06
WO2008024398A3 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
CN101563085A (zh) 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物
JP5844285B2 (ja) カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
JP2010501568A5 (enExample)
WO2020140959A1 (zh) 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用
ES3034157T3 (en) Modulators of potassium ion channels and uses thereof
Zhang et al. Design, synthesis and activity evaluation of indole-based double–Branched HDAC1 inhibitors
CN117736163A (zh) 一种苯基哌嗪衍生物或其药物学上的盐、制备方法及其在制备治疗疼痛药物中的应用
US8492588B2 (en) Benzyloxy anilide derivatives useful as potassium channel modulators
AU2013211531A1 (en) Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20091021